Alkermes (ALKS) Expected to Beat Earnings Estimates: Should You Buy?

Company Overview - Alkermes is expected to report a year-over-year decline in earnings, with a projected EPS of $0.41, reflecting a decrease of 43.1% compared to the previous year [3] - Revenues are anticipated to be $338.69 million, down 15.1% from the same quarter last year [3] Earnings Expectations - The earnings report is scheduled for July 29, and the actual results will significantly influence the stock price, depending on whether they meet or exceed expectations [2] - The consensus EPS estimate has been revised 1.03% lower in the last 30 days, indicating a reassessment by analysts [4] Earnings Surprise Prediction - The Most Accurate Estimate for Alkermes is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +4.94%, suggesting a likelihood of beating the consensus EPS estimate [12] - Alkermes currently holds a Zacks Rank of 3, which indicates a neutral outlook [12] Historical Performance - In the last reported quarter, Alkermes had an expected EPS of $0.28 but only delivered $0.13, resulting in a surprise of -53.57% [13] - Over the past four quarters, the company has only beaten consensus EPS estimates once [14] Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Exelixis is expected to report earnings of $0.63 per share, reflecting a year-over-year decline of 25% [18] - Exelixis has a higher Most Accurate Estimate leading to an Earnings ESP of +2.52% and a Zacks Rank of 2, indicating a strong likelihood of beating the consensus EPS estimate [19]